Skip to main content
New Year’s Sale — Build a balanced news diet with 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

Summary by The Manila Times
TARPON SPRINGS, Fla., December 31, 2025 - Allarity Therapeutics, Inc. ('Allarity” or the 'Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated...

2 Articles

The Manila TimesThe Manila Times
Lean Right

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

TARPON SPRINGS, Fla., December 31, 2025 - Allarity Therapeutics, Inc. ('Allarity” or the 'Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated...

·Manila, Philippines
Read Full Article
ADKhabarADKhabar

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

December 30, 2025 09:15 ET  | Source: Akari Therapeutics Plc TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today issued the following letter to shareholders from its President and Chief Executive Officer, Abizer Gaslightwala.                   […] The post Akari Therapeutics Issues 2025 End of Year L…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

ADKhabar broke the news in on Tuesday, December 30, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Tarpon Springs icon

Tarpon Springs

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal